RoosterBio is a technology company.
RoosterBio has raised $22.0M across 2 funding rounds.
RoosterBio has raised $22.0M in total across 2 funding rounds.
RoosterBio has raised $22.0M in total across 2 funding rounds.
RoosterBio's investors include AVANT BIO.
RoosterBio is a privately held biotechnology company that develops and manufactures high-volume, well-characterized adult human mesenchymal stem/stromal cells (hMSCs), paired with engineered media systems, genetic engineering tools, and extracellular vesicle (EV) production solutions to accelerate regenerative medicine commercialization[1][2][3][5]. It serves researchers, academic institutions, biopharma companies, and contract manufacturers in cell therapy, gene therapy, exosomes, tissue engineering, and bioprocessing by solving key challenges like high costs, scarcity, and complexity in scaling hMSCs from research to clinical trials and market[2][4][5]. The company drives growth by reducing costs from over $1,000 to under $10 per million cells, shortening development timelines, and enabling off-the-shelf cGMP products, supporting over 500 global partners and contributing to 350+ peer-reviewed publications[2][4][5].
RoosterBio was founded in 2013 by scientists who observed redundant efforts across labs to build mesenchymal stromal cell (MSC) banks, creating a bottleneck in regenerative medicine progress[4][6][9]. The idea emerged from recognizing that standardized, off-the-shelf hMSC products could simplify supply chains, standardize workflows, and speed preclinical-to-clinical translation, much like 3D printers fueled the maker movement[2][6]. Early traction came via grants like TEDCO’s Rural Business Innovation Program in 2015 for lab equipment and scale-up manufacturing, and a 2017 Maryland Stem Cell Research Fund commercialization grant that expanded cell bank production and hiring, growing the company to over 200 customers worldwide by enabling innovations in bioprinting, tissue engineering, and therapies for conditions like osteoarthritis[4].
RoosterBio rides the explosive growth in cell and gene therapies, regenerative medicine, and biofabrication, where scalable biomanufacturing is critical to unlocking a market projected to deliver life-saving treatments for osteoarthritis, cartilage defects, and beyond[1][4][5]. Timing aligns with rising demand for cGMP-compliant, off-the-shelf cells amid clinical trial surges, as traditional ad-hoc cell banking delays progress by years and millions in costs—RoosterBio removes this dam by standardizing supply chains[3][4][6]. Favorable forces include regulatory advancements (e.g., FDA Master Files) and industry shifts toward EVs and genetic engineering, positioning RoosterBio to influence the ecosystem by de-risking pipelines for 500+ partners and fostering a collaborative network of specialized experts[5][6].
RoosterBio is primed to expand its portfolio with innovations like RoosterHD™-EV chemically defined exosome media and pluripotent stem cell technologies, further shortening paths to commercialization amid booming advanced therapy demand[5][7]. Trends like AI-optimized bioprocessing, global clinical trial growth, and EV therapeutics will amplify its momentum, potentially evolving its role from supplier to full-service CDMO partner. As the "proclaimer of a new day for scalable therapies," RoosterBio will continue fueling a sustainable regenerative medicine industry, turning abundant cells into widespread patient impact[2].
RoosterBio has raised $22.0M across 2 funding rounds. Most recently, it raised $7.0M Series B in September 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2019 | $7.0M Series B | AVANT BIO | |
| Aug 1, 2019 | $15.0M Series B | AVANT BIO |